QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

JANX

QT47Janux Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
14.22
+0.07+0.49%
OverviewShort InterestFilings
JANXQT47Janux Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
14.22+0.49%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.91
Insider Own-
Shs Outstand60.98M
Perf Week4.10%
Market Cap862.93MForward P/E-EPS next Y-2.71Insider Trans-0.04%Shs Float-Perf Month2.97%
Enterprise Value832.67MPEG0.22EPS next Q-0.31Inst Own-Short Float-Perf Quarter0.42%
Income-111404083.00P/S39.93EPS this Y-89.18%Inst Trans-Short Ratio-Perf Half Y-2.94%
Sales21.61MP/B0.94EPS next Y-57.25%ROA-11.13%Short Interest-Perf YTD3.04%
Book/sh15.45P/C-EPS next 5Y-ROE-11.85%52W High35.34 -59.76%Perf Year-37.93%
Cash/sh15.68P/FCF-EPS past 3/5Y-ROIC-16.15%52W Low12.12 17.33%Perf 3Y-
Dividend Est.-EV/EBITDA-7.40Sales past 3/5Y3.57% -Gross Margin54.15%Volatility2.62% 2.67%Perf 5Y-
Dividend TTM-EV/Sales38.53EPS Y/Y TTM-43.75%Oper. Margin-726.34%ATR (14)0.57Perf 10Y-
Dividend Ex-Date-Quick Ratio17.01Sales Y/Y TTM36.36%Profit Margin-529.67%RSI (14)53.59Recom2.50
Dividend Gr. 3/5Y-Current Ratio17.01EPS Q/Q-2.63%SMA201.82%Beta1.36Target Price23.40
Payout0.00%Debt/Eq0.02Sales Q/Q-SMA50-1.29%Rel Volume1.32Prev Close14.15
Employees91LT Debt/Eq0.02EarningsAug 06SMA200-21.21%Avg Volume944.64KPrice14.22
IPO DateJun 11, 2021Option/ShortYes / YesEPS/Sales Surpr.25.03% 0.00%Net Debt/EBITDA0.27Volume1,251,085Change0.49%
Analyst Ratings
DateActionAnalystRatingTarget
May-11-26ReiteratedEvercore ISI$23 → $22
May-08-26ReiteratedWedbushOutperform$76 → $36
Apr-20-26DowngradeBarclaysOverweight → Underweight$29 → $14
Apr-15-26DowngradeUBSBuy → Neutral$57 → $15
Jan-20-26DowngradeClear StreetBuy → Hold
Jan-16-26ReiteratedPiper SandlerOverweight$30
Dec-17-25ReiteratedBarclaysOverweight$47 → $29
Dec-02-25ReiteratedUBS$69 → $57
Dec-02-25ReiteratedStifel Nicolaus$46 → $38
Dec-02-25ReiteratedH.C. Wainwright$70 → $45
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue151011
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A422
Gross Profit1389
Selling, General and Administrative Excl. Other264241
Research and Development5312668
Other Operating Expense0-2-2
Operating Income-66-158-99
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-21-44-30
Net Income Before Taxes-45-114-69
Income Taxes
000
Consolidated Net Income-45-114-69
Net Income From Continuing Operations-45-114-69
Net Income-45-114-69
EPS (Recurring)-0.91-1.83-1.28
EPS (Basic, Before Extraordinaries)-0.91-1.83-1.28
EPS (Diluted)-0.91-1.83-1.28
EBITDA-41-112-67
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio51.1985.56—
Gross Margin86.6780.0081.82
Operating Margin-440.00-1,580.00-900.00
Net Margin-300.00-1,140.00-627.27
Shares Outstanding546254
Market Capitalization768856—
Operating Lease Expense
———
Insider Trading Volume
$15.60$13.94$12.28$10.62$8.96● Close Price0.00K125.25K250.49K375.74K500.99KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Doyle Janeen NoelChief Corp. & Bus. Dev. OfcrJun 02 '26Sale14.034,05956,94475,941Jun 04 12:00 AM
Dobek MariaVice President, AccountingMay 11 '26Sale14.172,03828,87832,270May 13 12:00 AM
Meyer Andrew HollmanChief Business OfficerJan 02 '26Sale13.731,87925,79983,095Jan 02 12:00 AM
DiRaimondo ThomasChief Scientific OfficerJan 02 '26Sale13.732,50534,394124,425Jan 02 12:00 AM
Campbell David AlanPresident and CEOJan 02 '26Sale13.738,072110,829284,982Jan 02 12:00 AM
Winter Charles M.Chief Technical OfficerJan 02 '26Sale13.732,40132,96677,721Jan 02 12:00 AM
McIver ZachariahChief Medical OfficerJan 02 '26Sale13.732,71437,26323,286Jan 02 12:00 AM
Dobek MariaVice President, AccountingJan 02 '26Sale13.731,46220,07315,373Jan 02 12:00 AM
Meyer Andrew HollmanChief Business OfficerDec 01 '25Option Exercise10.596,66670,592114,768Dec 03 12:00 AM
Meyer Andrew HollmanChief Business OfficerDec 01 '25Sale32.983,333109,92984,974Dec 03 12:00 AM
Meyer Andrew HollmanChief Business OfficerNov 14 '25Option Exercise10.596,66670,592118,101Nov 14 12:00 AM
Meyer Andrew HollmanChief Business OfficerNov 14 '25Sale30.003,33399,99084,974Nov 14 12:00 AM
Meyer Andrew HollmanChief Business OfficerOct 28 '25Option Exercise6.7633,330225,378121,434Oct 30 12:00 AM
Meyer Andrew HollmanChief Business OfficerOct 28 '25Sale30.0616,665500,98782,139Oct 30 12:00 AM
Meyer Andrew HollmanChief Business OfficerMay 01 '25Option Exercise4.216,66628,06487,332May 02 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR